on HYBRIGENICS (EPA:ALHYG)
Inoviem Scientific Advances Drug Development with Patient-Centric Approach
Aton Group has provided an update on its subsidiary, Inoviem Scientific, emphasizing its innovative approach in drug development. Inoviem Scientific places patient samples at the heart of all development stages, from research to clinical practice.
The company integrates technologies for analyzing patient-derived samples with AI molecular characterization. This platform aids drug development from R&D to clinical decision-making, promoting personalized medicine over conventional models.
Two preclinical programs illustrate this model, allowing rapid functional analysis of drug candidates using patient samples. This approach offers biopharmaceutical partners essential translational data, potentially reducing timelines and costs.
Inoviem Scientific is solidifying its role as a strategic partner in early-stage drug discovery, highlighting its operational capabilities to meet growing demand for predictive preclinical models.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all HYBRIGENICS news